Mar 3 |
Cardiff Oncology Full Year 2023 Earnings: Beats Expectations
|
Mar 1 |
Nasdaq Surges 100 Points; ISM Manufacturing PMI Falls In February
|
Mar 1 |
Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results
|
Mar 1 |
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript
|
Feb 29 |
Cardiff Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation
|
Feb 29 |
Cardiff Oncology GAAP EPS of -$0.93 beats by $0.08, revenue of $0.48M beats by $0.2M
|
Feb 29 |
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
|
Feb 29 |
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
|
Feb 29 |
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
|
Feb 29 |
Earnings Scheduled For February 29, 2024
|